Mitsubishi Chemical v. Shanghai Auzone: RADICAVA ORS® Cases Consolidated in New Jersey
Mitsubishi Chemical Holdings Corporation filed a patent infringement action against Shanghai Auzone Biological Technology Co., Ltd. in the District of New Jersey, asserting three patents covering RADICAVA ORS®. Within 50 days of filing, the court consolidated this action with related proceedings into a single Lead Case (No. 25-3326) to promote judicial economy.
Three RADICAVA ORS® patent suits folded into one consolidated action
On October 15, 2025, Mitsubishi Chemical Holdings Corporation (acting through Mitsubishi Tanabe Pharma Corporation) filed a patent infringement complaint in the U.S. District Court for the District of New Jersey against Shanghai Auzone Biological Technology Co., Ltd. The suit asserts three U.S. patents — US12194025B2, US12310946B2, and US12285409B2 — all relating to RADICAVA ORS®, the oral suspension formulation of edaravone used in the treatment of ALS.
On December 4, 2025, just 50 days after filing, the court entered a consolidation order under Federal Rule of Civil Procedure 42(a) and Local Civil Rule 42.1, finding that this action and at least one other related case shared common questions of law or fact. Civil Action No. 25-3326 was designated the Lead Case, and No. 25-16665 was administratively closed. All future filings, discovery, case management, and trial proceedings are to be conducted exclusively under the Lead Case docket.
The rapid consolidation — achieved within 50 days and without opposition from any party — suggests coordinated enforcement strategy by Mitsubishi Tanabe Pharma against multiple Auzone entities (including U.S. and Australian affiliates) simultaneously. The substantive merits of the infringement claims, claim construction, and any damages or injunctive relief remain entirely unresolved and will be litigated in the Lead Case. The public record for this docket is silent on any licensing discussions or settlement activity.
Filing to Case Consolidated in 50 days
50 days from filing to administrative closure via consolidation order
Case consolidated: what the court’s order means for both parties
Consolidation under FRCP 42(a) is procedural, not a merits ruling
Under Federal Rule of Civil Procedure 42(a), a court may consolidate actions that share common questions of law or fact. The court’s order here reflects a finding of judicial economy — not any adjudication of infringement, validity, or damages. Civil Action No. 25-16665 is closed for administrative purposes only; the underlying claims survive and proceed in the Lead Case (No. 25-3326).
Procedural — no merits determinedMitsubishi gains a streamlined multi-defendant enforcement vehicle
Consolidation is broadly favourable for Mitsubishi Tanabe Pharma as plaintiff. Litigating three RADICAVA ORS® patent claims against multiple Auzone entities in a single docket reduces duplicative discovery and avoids inconsistent rulings. The unopposed nature of the order suggests defendants did not resist coordination, which may reflect an early pragmatic posture rather than concession on the merits.
Efficient multi-patent enforcementAuzone entities now face unified proceedings across three patents
For Shanghai Auzone and its affiliates, consolidation means coordinated discovery obligations and a single trial forum covering all three asserted patents. While consolidation does not prejudge liability, defendants must now respond to infringement allegations across US12194025B2, US12310946B2, and US12285409B2 in a single, resource-intensive proceeding. Invalidity and non-infringement defences will be tested together.
Three patents, one unified forumALS oral therapy IP enforcement signals heightened market protection posture
The simultaneous assertion of three patents covering RADICAVA ORS® against multiple international Auzone entities is consistent with an aggressive market-exclusivity strategy for edaravone oral formulations. Companies developing or commercialising oral edaravone products — particularly those with Chinese manufacturing links — should treat this consolidation as a signal that Mitsubishi Tanabe Pharma is actively monitoring and enforcing its RADICAVA ORS® portfolio.
Edaravone oral formulation risk zoneFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Mitsubishi Chemical Holdings Corporation | Company | Pharmaceutical IP holding group — holder of US12194025B2, US12310946B2, and US12285409B2Search in Eureka ↗ |
| Defendant | SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD. | Company | Chinese biotech company and its U.S. and Australian affiliates, allegedly infringing RADICAVA ORS® patentsSearch in Eureka ↗ |
| Plaintiff counsel | Bryan C. Diner | Attorney | Counsel for Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Justin James Hasford | Attorney | Counsel for Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff counsel | Stephen R. Donat | Attorney | Counsel for Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff counsel | William P. Deni | Attorney | Counsel for Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff law firm | Finnegan, Henderson, Farabow, Garrett & Dunner LLP | Law Firm | Representing Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons, PC | Law Firm | Representing Mitsubishi Chemical Holdings CorporationSearch in Eureka ↗ |
| Defendant counsel | CATHERINE SALERNO | Attorney | Counsel for SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing SHANGHAI AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order does not constitute a verdict on infringement, validity, or damages. The court’s finding of ‘common questions of law or fact’ under FRCP 42(a) is a threshold procedural determination. The phrase ‘no parties having opposed entry of this Order’ is notable — it suggests all defendants accepted consolidation, which may reflect strategic resource management rather than any concession on the underlying patent claims. All merits issues remain open in Lead Case No. 25-3326.
US12194025B2, US12310946B2 & US12285409B2 — RADICAVA ORS® edaravone oral formulation
The three asserted patents — US12194025B2, US12310946B2, and US12285409B2 — are U.S. utility patents covering aspects of RADICAVA ORS® (edaravone oral suspension), a formulation of the free-radical scavenger edaravone approved for treatment of amyotrophic lateral sclerosis (ALS). The application numbers (US18/311415, US18/932667, and US18/477752) indicate relatively recent prosecution, consistent with patent term extension strategies around a product that received FDA approval for its oral formulation in 2022.
Strategically, a three-patent portfolio covering different aspects of the same oral edaravone product — whether directed to formulation, method of use, or delivery — creates overlapping claim coverage that significantly raises the barrier for generic or biosimilar entry. For competitors developing oral ALS therapies or seeking to reference RADICAVA ORS® in regulatory filings, each patent represents a separate litigation exposure. The consolidated New Jersey action suggests Mitsubishi Tanabe Pharma is prepared to enforce all three aggressively.
Should you run an FTO against US12194025B2, US12310946B2 & US12285409B2?
Any company developing, manufacturing, or commercialising oral edaravone formulations — including ANDA filers, 505(b)(2) applicants, or international generic manufacturers with U.S. distribution — should treat this consolidated enforcement action as a trigger for immediate FTO analysis. The three patents span distinct application numbers suggesting different claim families; a single clearance opinion may not be sufficient to address all three.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim scope of US12194025B2, US12310946B2, and US12285409B2, identify prior art relevant to invalidity arguments, and surface related pending applications in the same patent families. This enables IP teams to assess both design-around options and IPR petition viability before any regulatory filing or product launch decision.
Run a freedom-to-operate analysis on US12194025B2 to assess your product’s exposure
Run FTO in Eureka →Similar ALS and oral pharmaceutical patent infringement cases in New Jersey
Related edaravone and ALS oral drug patent infringement actions filed in the District of New Jersey, including multi-patent and multi-defendant pharmaceutical enforcement cases.
What this case signals for the ALS therapy and specialty pharma IP landscape
Mitsubishi’s coordinated multi-patent, multi-defendant filing and rapid consolidation reveals an enforcement posture that warrants close attention from edaravone and ALS drug developers.
Multi-entity enforcement is a deliberate deterrence signal
Filing simultaneously against Shanghai Auzone’s Chinese, U.S., and Australian entities — and securing rapid consolidation without opposition — suggests a pre-planned enforcement strategy. Companies in the edaravone oral formulation space should assume that Mitsubishi Tanabe Pharma has mapped the Auzone corporate structure and is treating all affiliates as a single litigation target.
Three overlapping patents create a formidable invalidity challenge
Asserting three separate U.S. patents (US12194025B2, US12310946B2, US12285409B2) covering RADICAVA ORS® raises the cost and complexity of any invalidity challenge. Defendants must mount three separate IPR or invalidity analyses. For would-be competitors, this layered patent portfolio is a strong indicator that freedom-to-operate analysis is essential before market entry.
Mitsubishi v SHANGHAI — key questions answered
The court consolidated Case No. 25-16665 with related actions into Lead Case No. 25-3326 under FRCP 42(a). This is a procedural step — not a merits ruling. All infringement, validity, and damages issues for RADICAVA ORS® patents US12194025B2, US12310946B2, and US12285409B2 will be litigated in the Lead Case.
Mitsubishi Chemical Holdings Corporation, through Mitsubishi Tanabe Pharma Corporation, asserted three U.S. patents: US12194025B2 (App. No. US18/311415), US12310946B2 (App. No. US18/932667), and US12285409B2 (App. No. US18/477752). All three relate to RADICAVA ORS®, the oral suspension formulation of edaravone for ALS treatment.
The consolidation order references three Auzone entities: Shanghai Auzone Biological Technology Co., Ltd. (China), Auzone Biological Technology (USA) Ltd., and Auzone Biological Technology Pty Ltd (Australia). This multi-jurisdictional defendant structure suggests Mitsubishi Tanabe Pharma is targeting the full corporate chain involved in the allegedly infringing product.
Yes. While Case No. 25-16665 was administratively closed, the underlying infringement claims are fully active and proceeding in Lead Case No. 25-3326 in the District of New Jersey. No merits rulings, claim construction orders, or dispositive motions have been issued as of the consolidation date.
The fact that no party opposed consolidation of the RADICAVA ORS® patent actions is procedurally notable. For defendants, it may reflect a strategic decision to manage discovery costs efficiently across multiple cases rather than any concession on infringement or validity. For the plaintiff, unopposed consolidation accelerates the path to a single, coordinated trial forum.
PatSnap Eureka searches patents and litigation data to answer instantly.